Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sleijfer

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2009
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali, L Jost, S Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali, L Jost, S Sleijfer, et al.
Cancer|March 5, 1998
Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicityS Sleijfer, Z Vujaskovic, P C Limburg, et al.
Current Cancer Drug Targets|May 16, 2009
The applicability of mTOR inhibition in solid tumorsI R H M Konings, J Verweij, E A C Wiemer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatinS Sleijfer, T W van der Mark, H Schraffordt Koops, et al.
British Journal of Cancer|January 1, 1995
Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effectS Sleijfer, T W van der Mark, H Schraffordt Koops, et al.
Seminars in Cancer Biology|November 7, 2017
Breast cancer genomics and immuno-oncological markers to guide immune therapiesD Hammerl, M Smid, A M Timmermans, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53S Sleijfer, T K Le, S de Jong, et al.
Cytotherapy|December 7, 2006
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgeneC H J Lamers, P van Elzakker, S C L Langeveld, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 9, 2019
Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort studyM Vos, W C Boeve, T M van Ginhoven, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2009
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali, L Jost, S Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali, L Jost, S Sleijfer, et al.
Cancer|March 5, 1998
Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicityS Sleijfer, Z Vujaskovic, P C Limburg, et al.
Current Cancer Drug Targets|May 16, 2009
The applicability of mTOR inhibition in solid tumorsI R H M Konings, J Verweij, E A C Wiemer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatinS Sleijfer, T W van der Mark, H Schraffordt Koops, et al.
British Journal of Cancer|January 1, 1995
Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effectS Sleijfer, T W van der Mark, H Schraffordt Koops, et al.
Seminars in Cancer Biology|November 7, 2017
Breast cancer genomics and immuno-oncological markers to guide immune therapiesD Hammerl, M Smid, A M Timmermans, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53S Sleijfer, T K Le, S de Jong, et al.
Cytotherapy|December 7, 2006
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgeneC H J Lamers, P van Elzakker, S C L Langeveld, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 9, 2019
Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort studyM Vos, W C Boeve, T M van Ginhoven, et al.
Pageof 10